“…Relevant changes of therapeutic management were reported in 18-52% of advanced NSCLC [5,12,18,21]. In patients with CUP, 44-63% had a different therapy after FDG PET [13,16]. In PC, the tracer 11C-choline promises some improvements in determination of metastases [2].…”